March 14, 2025
FDA clears PDS Biotechnology’s Versamune MUC1 combo for mCRC
The US Food and Drug Administration (FDA) has granted clearance for PDS Biotechnology's investigational new drug (IND) application to assess Versamune MUC1 plus PDS01ADC for the treatment of unresectable, metastatic colorectal carcinoma (mCRC).